Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Systemic therapies for MPPGs are limited. MPPGs are cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Camilo, Subbiah, Vivek, Stephen, Bettzy, Ma, Junsheng, Milton, Denai, Xu, Mingxuan, Zarifa, Abdualrazzak, Akhmedzhanov, Fechukwu Omolara, Tsimberidou, Apostolia, Habra, Mouhammed Amir, Rodon Anhert, Jordi, Fu, Siqing, Naing, Aung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465458/
https://www.ncbi.nlm.nih.gov/pubmed/32824391
http://dx.doi.org/10.3390/cancers12082307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465458/
https://www.ncbi.nlm.nih.gov/pubmed/32824391
http://dx.doi.org/10.3390/cancers12082307

Ejemplares similares